Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162981 · ClinicalTrials.gov registry record · Phase 2
Clobazam in Subjects With Lennox-Gastaut Syndrome
A Phase 2 study, sponsored by Lundbeck.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00162981 is a Phase 2 study that has completed, run by Lundbeck. The registered enrollment target is 68 participants.
The verdict
NCT00162981, a Phase 2 study, has completed, sponsored by Lundbeck.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in subjects 2 to 30 years of age with Lennox-Gastaut Syndrome (LGS). Subjects will be enrolled at approximately 10 investigational sites in the U.S. for up to 15 weeks. Subjects will be randomly assigned to either a low dose or a high dose. The study will include a baseline period, a titration period and a maintenance period. After the maintenance period, subjects will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.
Interventions
- DRUG Clobazam Low Dose
- DRUG Clobazam High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162981
The ClinicalTrials.gov registry entry for NCT00162981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lundbeck, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clobazam Low Dose is the first listed.
NCT00162981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162981 about?
NCT00162981 is a clinical study titled "Clobazam in Subjects With Lennox-Gastaut Syndrome". The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in subjects 2 to 30 years of age with Lennox-Gastaut Syndrome (LGS). Subjects will be enrolled at approximately 10 investigationa...
What is the current status of trial NCT00162981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2005-10. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00162981?
The interventions under investigation include: Clobazam Low Dose (DRUG), Clobazam High Dose (DRUG).
Who is sponsoring clinical trial NCT00162981?
This trial is sponsored by Lundbeck, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.